Triche
Laboratory

Translational Biological Informatics

Acute myeloid leukemia (AML) is an aggressive blood cancer with dismal survival rates and extreme variability from patient to patient. This poses a serious challenge to the development of effective new therapies.

After a decades-long drought, the Food and Drug Administration (FDA) approved four new drugs for the disease in 2017. One of these, Idhifa (enasidenib), resulted directly from discoveries in major genomic profiling projects. A transformative drug was brought to bear in some of the worst-prognosis cases of the disease, by combining functional studies with insight from data-intensive molecular profiling. A New England Journal of Medicine editorial heralded the first of these studies as “the beginning of the end of the beginning”—as a chapter closed on pure profiling studies, a new chapter has opened, where large-scale clinical trials are wedded to deep characterization of patients and their responses.

In this new chapter, perhaps best exemplified by the genetic diversity of leukemia both between and within patients, there is no one cure for cancer—there are thousands. As novel agents prove their worth, a new problem is emerging: how can we couple the statistical rigor of randomized trials—a foundational tool of modern medicine—with the recognition that what we have long treated as a single disease in fact contains dozens?

The Triche Laboratory is focused on reconciling these opposing forces. Quick-to-fail early trial designs, enriched for specific patients with a high probability of response, can hasten the real-world testing of new drugs, which in turn are prioritized by shared molecular phenotypes. Discovering groups of patients whose disease shares molecular vulnerabilities, regardless of genotype or morphology, is the domain of statistical learning, and in this domain, it is an open research question how best to quantify uncertainty.

Ultimately, the randomized clinical trial provides the most powerful evidence in medicine, but trials are expensive, slow, and present unique ethical challenges, especially in children. Interpretable and rigorous statistical approaches are required; sick children will never be entrusted to “black box” machine learning approaches by their physicians.

We believe that cancers of the blood can serve as a model for more genomically and physically complex solid tumors, and we believe that insights from pediatric disease can impact both the understanding and treatment of adult disease. Children are not just small adults; the evolutionary history of pediatric disease is necessarily different from that in adults.  The quiet genomic landscapes of pediatric cancer forces us to look closely, and in doing so, we can uncover subtle but fundamental forces shaping malignant evolution. For every malignant cell, a premalignant cell is among its ancestors, with a tiny yet crucial difference marking the change.

Cancers of the blood happen to be the best characterized in this respect, with clonal hematopoiesis (a loss of diversity in the millions of blood cells produced every minute) being an active topic of discussion: when does prevention become hypochondria? This, too, will eventually yield to analysis, with (one hopes) useful lessons for other types of cancer. Though our primary expertise is in hematological (blood) cancers, we also collaborate broadly with physicians to study a variety of pediatric solid tumors, to understand how liquid tumor biology can illuminate solid tumor treatment, and where fundamental differences prevent this.

Visit us on Github!

Github

Our Impact

We’re raising thousands to save millions.

We’re turning hope into action for the millions of people around the world affected by diseases like cancer and Parkinson’s. Find out how you can help us make a difference.

  • 141 peer-reviewed papers published in 2025, 74 of which were in high-impact journals
  • 15 VAI-SU2C Epigenetics Dream Team clinical trials launched to date
  • 10 clinical trials and related projects supported by VAI through the International Linked Clinical Trials Program

Tim Triche, Jr., Ph.D.

Associate Professor, Department of Epigenetics

Faculty Advisor, Bioinformatics and Biostatistics Core

Areas of Expertise

Leukemia, biostatistics, computational biology, next-generation sequencing

Biography

Dr. Tim Triche, Jr., earned his A.B. in chemistry from Cornell University, followed by an M.S. in biostatistics and a Ph.D. in statistical genetics from University of Southern California. Prior to joining Van Andel Institute’s Department of Epigenetics in 2017, he served as a postdoctoral fellow in the Jane Anne Nohl Division of Hematology at USC’s Norris Comprehensive Cancer Center, where he studied the roles of cellular and immune senescence in benign and malignant blood disorders, including acute myeloid leukemia and pediatric leukemia. He has been a key member of The Cancer Genome Atlas Research Network since 2011, and has contributed to more than a dozen of the consortium’s publications in journals such as Nature and Cell. As a statistician with interests in both basic and translational research, Dr. Triche’s work focuses on improving patient outcomes and quality of life through the design of randomized clinical trials, which are critical components of moving promising therapies from the lab to the doctor’s office.

Memberships

American Society of Hematology
Global Alliance for Genomic Health
American Association for Cancer Research
International Society of Paediatric Oncology

Selected Publications

# Equal contributions * Co-corresponding authors

Jennifer Brooks

Senior Administrative Assistant I, Department of Epigenetics

Nathaniel Buteyn, Ph.D.

Research Scientist, Department of Epigenetics

Sophia Chaudhry, Ph.D.

Postdoctoral Fellow, Triche Laboratory

Colton Dysart

Laboratory Aide, Department of Epigenetics

Alexandria Eiken, Ph.D.

Postdoctoral Fellow, Janssens & Triche Laboratories

Eve Gardner

Lab Manager, Department of Epigenetics

Lauren Harmon, Ph.D.

M.D./Ph.D. Student

Research Focus: Genetic epidemiology of pediatric acute myeloid leukemia

Lia Hooker, M.S.

Ph.D. Student, VAI Graduate School

Research Focus: Determinants of treatment outcomes in multiple myeloma

Samantha LaMantia

Assistant Research Technician, Department of Epigenetics

Hoang-Le Mai Tran, M.Sc.

Research Data Technician, Department of Epigenetics

Lab Alumni

Caliese Beckford

Intern

Erik Bouwhuis

Research Data Technician

Connor Burke, M.D.

Intern

Max Chauhan, M.S.

Intern

Cecilia Conrad

Intern

Zach DeBruine, Ph.D.

Postdoctoral Fellow

David Dies, PSM

Research Data Technician

Lauren Dunkelberg, B.A.

Senior Administrative Assistant

Jessica Elderkin, M.D.

Intern

Sara Filippelli

Intern

Marco Garcia, M.D.

Intern

Lyong Heo, M.S.

Computational Biologist

Pamela Himadewi, B.S.

Assistant Research Technician

Peter Huang, Ph.D.

MSU Graduate Student

Ava Jensen

Assistant Research Technician

Ben Johnson, Ph.D.

Postdoctoral Fellow

Dahlya Kamarudin

Research Technician

Sonia Ling

Intern

Kadian Morrison

Intern

Mary Rhodes, B.S.

Lab Manager

Vincent Sartori

Intern

Noor Sohail, B.S.

Intern

Jessica Tagudar, M.S.

Intern

Ember Tokarski

Research Data Technician

Jordan Veldboom, PSM

Research Data Technician

Nicole Ver Beek

Intern